glp-1 and parkinson's Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease disease | Journal of Biomedical Science Use of Glucagon-Like Peptide-1 |

New Indications : GLP-1 drugs are being tested for obesity-related conditions (NASH/non-alcoholic steatohepatitis, cardiovascular risk reduction, etc.)

This reduction in systemic inflammation contributes to improved energy levels, better sleep quality, reduced joint pain, and the general sense of vitality that people report during months two and three

Now that telehealth companies can no longer sell the cheaper compounded medication, its unclear whether or not hell be able to afford to stay on a GLP-1

Then urgency

Older glucose lowering therapies demonstrated efficacy with respect to achieving glycemic targets but lacked benefits for hard kidney or cardiovascular (CV) outcomes [1]

Most participants tolerated the medication well by the end of the study period